SubsidieMeestersPoint of care diagnostic solution for definitive differentiation of true and false threatened preterm labour cases
INNITIUS aims to optimize TPTL diagnosis with Fine Birth, a non-invasive AI-driven device that assesses cervical tissue consistency, seeking €2.5M for further development and regulatory approval.
Projectdetails
Introduction
Threatened Preterm Labour (TPTL) is the leading cause of preterm births and hospitalization during pregnancy. With 45 million cases annually, treatments and resources are not being properly allocated towards the patients who need them.
Importance of Efficient Diagnosis
Efficient diagnosis of TPTL is the key to optimizing treatments; however, current methods are ineffective at detecting true events.
Innovation by INNITIUS
INNITIUS has developed Fine Birth, the first non-invasive PoC diagnostic device that uses torsional waves and AI to directly measure a patient’s cervical tissue consistency to identify the risk of TPTL in real-time.
Features of Fine Birth
- Objective
- Accurate
- Fast
- Can be operated by staff with minimal training
Development Status
We have reached TRL6, testing the prototype in a multicentre clinical study with over 300 patients in 7 sites.
Funding Requirements
We need €2.5 million to fully develop and validate our AI software, conduct a multicentre pivotal clinical trial, and obtain regulatory approval, which we will be able to finalize with the support of the EIC.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.342.835 |
| Totale projectbegroting | € 3.346.908 |
Tijdlijn
| Startdatum | 1-4-2023 |
| Einddatum | 31-3-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ULTRASOUND-INNOVATION MEDTECH SOCIEDAD LIMITADApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market. | EIC Accelerator | € 2.498.816 | 2024 | Details |
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implementNEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Paradigm shift in stroke: accurate diagnosis and evaluation of all treatment options in any hospital, at any timeMethinks aims to transform stroke diagnosis by enabling all hospitals to evaluate treatment options using standard imaging, reducing time-to-treatment and improving patient outcomes globally. | EIC Accelerator | € 2.495.415 | 2023 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement
NEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials.
Paradigm shift in stroke: accurate diagnosis and evaluation of all treatment options in any hospital, at any time
Methinks aims to transform stroke diagnosis by enabling all hospitals to evaluate treatment options using standard imaging, reducing time-to-treatment and improving patient outcomes globally.
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PELVIc Floor Evaluation live TRACKing – Real-time prediction of perineal traumaPELVITRACK aims to prevent pelvic floor disorders by developing a real-time monitoring solution for perineal tearing during vaginal deliveries through interdisciplinary research and innovative technologies. | EIC Pathfinder | € 3.209.102 | 2025 | Details |
Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic InterventionsMITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs. | EIC Transition | € 2.100.238 | 2022 | Details |
Early Moves at Home: a deployable and scalable serviceHet project richt zich op het vroegtijdig diagnosticeren van ontwikkelingsstoornissen bij hoog-risico pasgeborenen thuis, om de ontwikkeling van kinderen te verbeteren en zorgkosten te verlagen. | Mkb-innovati... | € 200.000 | 2022 | Details |
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritizationValo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates. | EIC Transition | € 2.226.280 | 2023 | Details |
Development and Validation of ‘findtb’, A Novel Digital Tool for Tuberculosis Triage in Children - Using Innovative Methodologies and an Interdisciplinary ApproachThe Find-TB project aims to develop and validate a digital triage tool using predictive models to enhance TB detection in children, reducing morbidity and mortality in high-burden settings. | ERC Consolid... | € 1.999.788 | 2024 | Details |
PELVIc Floor Evaluation live TRACKing – Real-time prediction of perineal trauma
PELVITRACK aims to prevent pelvic floor disorders by developing a real-time monitoring solution for perineal tearing during vaginal deliveries through interdisciplinary research and innovative technologies.
Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions
MITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs.
Early Moves at Home: a deployable and scalable service
Het project richt zich op het vroegtijdig diagnosticeren van ontwikkelingsstoornissen bij hoog-risico pasgeborenen thuis, om de ontwikkeling van kinderen te verbeteren en zorgkosten te verlagen.
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization
Valo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates.
Development and Validation of ‘findtb’, A Novel Digital Tool for Tuberculosis Triage in Children - Using Innovative Methodologies and an Interdisciplinary Approach
The Find-TB project aims to develop and validate a digital triage tool using predictive models to enhance TB detection in children, reducing morbidity and mortality in high-burden settings.